Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (786)	3/31/1998 9:20:00 AM
From: JZGalt	Read Replies (1) \| Respond to of 887

Where is DepoMorphine in the FDA process? I'm guilty of losing track of it after the FDA haircut because of the DepoCyt problems. DepoMorphine was the reason I took an initial position.

To: Dr. John M. de Castro who wrote (786)	4/1/1998 7:40:00 PM
From: Czechsinthemail	Respond to of 887

John, Regarding the difficulties adjusting dosage with DepoMorphine, it would seem to me that increases the likelihood that you would either be under- or over-dosing patients. If you end up under-dosing to avoid over-dosing, might that not necessitate additional morphine injections to produce an adequate dose? If that concern is present, it may produce a reluctance to use DepoMorphine that either means it isn't used much or its price and margins might have to be very low if there was a high likelihood of having to administer additional morphine. Your thoughts? Baird